{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:29:33Z","timestamp":1789010973574,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T00:00:00Z","timestamp":1629849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T00:00:00Z","timestamp":1629849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The improved prognosis of classic Hodgkin lymphoma (cHL) has been accompanied by elevated risks of non\u2013cancer-specific death (non-CSD). The aim of this study was to verify the occurrence of non-CSD and its effect on rates of overall survival among adult patients with cHL.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>To ensure sufficient follow-up time, we analyzed retrospective data from patients aged \u226520\u2009years with cHL that was diagnosed between 1983 and 2005 in the Surveillance, Epidemiology, and End Results (SEER) database. Logistic regression was applied to analyze the non-CSD occurrence in relation to all factors. Using Fine-Gray\u2019s method, we calculated the cumulative incidences of CSD and non-CSD. Stacked cumulative incidence plots and ratio of non-CSD to all causes of death were applied to evaluate the effect of non-CSD on rates of overall survival. Finally, we analyzed long-term mortality through Cox proportional hazard regression analysis and competing risk regression analysis to emphasize a more appropriate model of survival for patients with cHL.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among the 18,518 patients included, there were 3768 cases of CSD (20.3%) and 3217 of non-CSD (17.4%). Older age, earlier period, male sex, unmarried status, mixed cellularity (MC) and lymphocyte-depletion (LD) histological subtype, and patients received radiotherapy (RT) only were associated with more non-CSD according to binary logistic analysis. The cumulative incidence of non-CSD exceeded CSD after approximately 280\u2009months follow-up. The most common causes of non-CSDs were cardiovascular disease, subsequent primary neoplasms, infectious diseases, accidents, and suicide. In a Cox proportional hazards model, patients who were black, unmarried, at an advanced stage or underwent chemotherapy (CT) alone were at greater risk of mortality than were white patients, who were married, at an early stage, and underwent combined modality; these populations were also found to be at greater risk for CSD in a competing risk model, but the risk of non-CSD did not differ significantly according to race and marital status, patients with early-stage disease and who underwent RT only were found to be at higher risk of non-CSD instead.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Lymphoma was the cause of death in most patients who died, but non-CSD was not unusual. Patients with cHL should be monitored closely for signs of cardiovascular disease and malignant tumors. Rates of overall survival of patients were diminished by non-CSD, and a competing risk model was more suitable for establishing the prognosis than was the Cox proportional hazards model.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08683-x","type":"journal-article","created":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T20:02:47Z","timestamp":1629921767000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Causes of death and effect of non-cancer-specific death on rates of overall survival in adult classic Hodgkin lymphoma: a populated-based competing risk analysis"],"prefix":"10.1186","volume":"21","author":[{"given":"Jie","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengqiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fujue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuoting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaige","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhencang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianmin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqian","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,25]]},"reference":[{"issue":"2","key":"8683_CR1","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3322\/caac.21438","volume":"68","author":"S Shanbhag","year":"2018","unstructured":"Shanbhag S, Ambinder RF. Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin. 2018;68(2):116\u201332. https:\/\/doi.org\/10.3322\/caac.21438.","journal-title":"CA Cancer J Clin"},{"issue":"15","key":"8683_CR2","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1182\/blood-2018-02-824045","volume":"131","author":"LH Sehn","year":"2018","unstructured":"Sehn LH. Introduction to a review series on Hodgkin lymphoma: change is here. Blood. 2018;131(15):1629\u201330. https:\/\/doi.org\/10.1182\/blood-2018-02-824045.","journal-title":"Blood"},{"issue":"9","key":"8683_CR3","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.ejca.2010.02.010","volume":"46","author":"CE Kiserud","year":"2010","unstructured":"Kiserud CE, Loge JH, Fossa A, Holte H, Cvancarova M, Fossa SD. Mortality is persistently increased in Hodgkin's lymphoma survivors. Eur J Cancer. 2010;46(9):1632\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2010.02.010.","journal-title":"Eur J Cancer"},{"issue":"18","key":"8683_CR4","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1200\/JCO.2003.07.131","volume":"21","author":"BM Aleman","year":"2003","unstructured":"Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van't Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol. 2003;21(18):3431\u20139. https:\/\/doi.org\/10.1200\/JCO.2003.07.131.","journal-title":"J Clin Oncol"},{"issue":"2","key":"8683_CR5","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1182\/blood-2010-06-291328","volume":"117","author":"SL Galper","year":"2011","unstructured":"Galper SL, Yu JB, Mauch PM, Strasser JF, Silver B, Lacasce A, et al. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood. 2011;117(2):412\u20138. https:\/\/doi.org\/10.1182\/blood-2010-06-291328.","journal-title":"Blood"},{"issue":"8","key":"8683_CR6","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1080\/10428190802140873","volume":"49","author":"S Myrehaug","year":"2008","unstructured":"Myrehaug S, Pintilie M, Tsang R, Mackenzie R, Crump M, Chen Z, et al. Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma. 2008;49(8):1486\u201393. https:\/\/doi.org\/10.1080\/10428190802140873.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"8683_CR7","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1001\/jamaoncol.2018.5911","volume":"5","author":"SR Jhawar","year":"2019","unstructured":"Jhawar SR, Rivera-Nunez Z, Drachtman R, Cole PD, Hoppe BS, Parikh RR. Association of Combined Modality Therapy vs chemotherapy alone with overall survival in early-stage pediatric Hodgkin lymphoma. JAMA Oncol. 2019;5(5):689\u201395. https:\/\/doi.org\/10.1001\/jamaoncol.2018.5911.","journal-title":"JAMA Oncol"},{"issue":"Suppl 4","key":"8683_CR8","doi-asserted-by":"publisher","first-page":"iv25","DOI":"10.1093\/annonc\/mdj995","volume":"17","author":"MS Hertzberg","year":"2006","unstructured":"Hertzberg MS, Crombie C, Benson W, Taper J, Gottlieb D, Bradstock KF. Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma. Ann Oncol. 2006;17(Suppl 4):iv25\u201330.","journal-title":"Ann Oncol"},{"issue":"31\u201332","key":"8683_CR9","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3238\/arztebl.2018.0535","volume":"115","author":"PJ Br\u00f6ckelmann","year":"2018","unstructured":"Br\u00f6ckelmann PJ, Eichenauer DA, Jakob T, Follmann M, Engert A, Skoetz N. Hodgkin lymphoma in adults. Dtsch Arztebl Int. 2018;115(31\u201332):535\u201340. https:\/\/doi.org\/10.3238\/arztebl.2018.0535.","journal-title":"Dtsch Arztebl Int"},{"issue":"35","key":"8683_CR10","doi-asserted-by":"publisher","first-page":"4083","DOI":"10.2217\/fon-2019-0178","volume":"15","author":"J Wu","year":"2019","unstructured":"Wu J, Man D, Wang K, Li L. Impact of nonappendiceal cancer-specific death on overall survival: a competing risk analysis. Future Oncol. 2019;15(35):4083\u201393. https:\/\/doi.org\/10.2217\/fon-2019-0178.","journal-title":"Future Oncol"},{"issue":"13","key":"8683_CR11","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1002\/cncr.30617","volume":"123","author":"J Fu","year":"2017","unstructured":"Fu J, Wu L, Jiang M, Li D, Jiang T, Fu W, et al. Real-world impact of non-breast cancer-specific death on overall survival in resectable breast cancer. Cancer. 2017;123(13):2432\u201343. https:\/\/doi.org\/10.1002\/cncr.30617.","journal-title":"Cancer"},{"issue":"4","key":"8683_CR12","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/cam4.1280","volume":"7","author":"A Ebied","year":"2018","unstructured":"Ebied A, Thanh Huan V, Makram OM, Sang TK, Ghorab M, Ngo HT, et al. The role of primary lymph node sites in survival and mortality prediction in Hodgkin lymphoma: a SEER population-based retrospective study. Cancer Med. 2018;7(4):953\u201365. https:\/\/doi.org\/10.1002\/cam4.1280.","journal-title":"Cancer Med"},{"issue":"54","key":"8683_CR13","doi-asserted-by":"publisher","first-page":"92978","DOI":"10.18632\/oncotarget.21722","volume":"8","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Zhang J, Zeng H, Zhou XH, Zhou HB. Nomograms for predicting the overall and cancer-specific survival of patients with classical Hodgkin lymphoma: a SEER-based study. Oncotarget. 2017;8(54):92978\u201388. https:\/\/doi.org\/10.18632\/oncotarget.21722.","journal-title":"Oncotarget"},{"issue":"1","key":"8683_CR14","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ijrobp.2015.02.012","volume":"92","author":"NK Gerber","year":"2015","unstructured":"Gerber NK, Atoria CL, Elkin EB, Yahalom J. Characteristics and outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma versus those with classical Hodgkin lymphoma: a population-based analysis. Int J Radiat Oncol Biol Phys. 2015;92(1):76\u201383. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.02.012.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"8683_CR15","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/cam4.655","volume":"5","author":"M Koshy","year":"2016","unstructured":"Koshy M, Fairchild A, Son CH, Mahmood U. Improved survival time trends in Hodgkin's lymphoma. Cancer Med. 2016;5(6):997\u20131003. https:\/\/doi.org\/10.1002\/cam4.655.","journal-title":"Cancer Med"},{"issue":"16","key":"8683_CR16","doi-asserted-by":"publisher","first-page":"5300","DOI":"10.1158\/1078-0432.CCR-07-0927","volume":"14","author":"M Provencio","year":"2008","unstructured":"Provencio M, Millan I, Espana P, Sanchez AC, Sanchez JJ, Cantos B, et al. Analysis of competing risks of causes of death and their variation over different time periods in Hodgkin's disease. Clin Cancer Res. 2008;14(16):5300\u20135. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-0927.","journal-title":"Clin Cancer Res"},{"key":"8683_CR17","doi-asserted-by":"crossref","unstructured":"Matasar MJ, Ford JS, Riedel ER, Salz T, Oeffinger KC, Straus DJ. Late morbidity and mortality in patients with Hodgkin's lymphoma treated during adulthood. J Natl Cancer Inst. 2015;107(4):djv018. http:\/\/doi.org\/10.1093\/jnci\/djv018.","DOI":"10.1093\/jnci\/djv018"},{"issue":"31","key":"8683_CR18","doi-asserted-by":"publisher","first-page":"3869","DOI":"10.1200\/JCO.2013.49.6489","volume":"31","author":"AA Aizer","year":"2013","unstructured":"Aizer AA, Chen MH, McCarthy EP, Mendu ML, Koo S, Wilhite TJ, et al. Marital status and survival in patients with cancer. J Clin Oncol. 2013;31(31):3869\u201376. https:\/\/doi.org\/10.1200\/JCO.2013.49.6489.","journal-title":"J Clin Oncol"},{"issue":"31","key":"8683_CR19","doi-asserted-by":"publisher","first-page":"51016","DOI":"10.18632\/oncotarget.16879","volume":"8","author":"F Wang","year":"2017","unstructured":"Wang F, Xie X, Yang X, Jiang G, Gu J. The influence of marital status on the survival of patients with Hodgkin lymphoma. Oncotarget. 2017;8(31):51016\u201323. https:\/\/doi.org\/10.18632\/oncotarget.16879.","journal-title":"Oncotarget"},{"issue":"32","key":"8683_CR20","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1200\/JCO.19.00812","volume":"37","author":"JM Kahn","year":"2019","unstructured":"Kahn JM, Kelly KM, Pei Q, Bush R, Friedman DL, Keller FG, et al. Survival by race and ethnicity in pediatric and adolescent patients with Hodgkin lymphoma: a Children's oncology group study. J Clin Oncol. 2019;37(32):3009\u201317. https:\/\/doi.org\/10.1200\/JCO.19.00812.","journal-title":"J Clin Oncol"},{"issue":"15","key":"8683_CR21","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1182\/blood-2017-09-772632","volume":"131","author":"A Mottok","year":"2018","unstructured":"Mottok A, Steidl C. Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies. Blood. 2018;131(15):1654\u201365. https:\/\/doi.org\/10.1182\/blood-2017-09-772632.","journal-title":"Blood"},{"issue":"5","key":"8683_CR22","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1002\/1097-0142(19830301)51:5<925::AID-CNCR2820510527>3.0.CO;2-O","volume":"51","author":"PM Mauch","year":"1983","unstructured":"Mauch PM, Weinstein H, Botnick L, Belli J, Cassady JR. An evaluation of long-term survival and treatment complications in children with Hodgkin's disease. Cancer. 1983;51(5):925\u201332. https:\/\/doi.org\/10.1002\/1097-0142(19830301)51:5<925::AID-CNCR2820510527>3.0.CO;2-O.","journal-title":"Cancer"},{"issue":"22","key":"8683_CR23","doi-asserted-by":"publisher","first-page":"4238","DOI":"10.1200\/JCO.2001.19.22.4238","volume":"19","author":"OW Press","year":"2001","unstructured":"Press OW, LeBlanc M, Lichter AS, Grogan TM, Unger JM, Wasserman TH, et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol. 2001;19(22):4238\u201344. https:\/\/doi.org\/10.1200\/JCO.2001.19.22.4238.","journal-title":"J Clin Oncol"},{"issue":"19","key":"8683_CR24","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1200\/JCO.2003.03.023","volume":"21","author":"A Engert","year":"2003","unstructured":"Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's lymphoma study group. J Clin Oncol. 2003;21(19):3601\u20138. https:\/\/doi.org\/10.1200\/JCO.2003.03.023.","journal-title":"J Clin Oncol"},{"issue":"19","key":"8683_CR25","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1200\/JCO.2005.05.2746","volume":"24","author":"EM Noordijk","year":"2006","unstructured":"Noordijk EM, Carde P, Dupouy N, Hagenbeek A, Krol AD, Kluin-Nelemans JC, et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol. 2006;24(19):3128\u201335. https:\/\/doi.org\/10.1200\/JCO.2005.05.2746.","journal-title":"J Clin Oncol"},{"issue":"4","key":"8683_CR26","first-page":"Cd007110","volume":"4","author":"O Blank","year":"2017","unstructured":"Blank O, von Tresckow B, Monsef I, Specht L, Engert A, Skoetz N. Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma. Cochrane Database Syst Rev. 2017;4(4):Cd007110.","journal-title":"Cochrane Database Syst Rev"},{"issue":"21","key":"8683_CR27","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","volume":"327","author":"GP Canellos","year":"1992","unstructured":"Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327(21):1478\u201384. https:\/\/doi.org\/10.1056\/NEJM199211193272102.","journal-title":"N Engl J Med"},{"issue":"2","key":"8683_CR28","first-page":"155","volume":"75","author":"AP Anselmo","year":"1990","unstructured":"Anselmo AP, Cartoni C, Bellantuono P, Maurizi-Enrici R, Aboulkair N, Ermini M. Risk of infertility in patients with Hodgkin's disease treated with ABVD vs MOPP vs ABVD\/MOPP. Haematologica. 1990;75(2):155\u20138.","journal-title":"Haematologica"},{"issue":"4","key":"8683_CR29","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1200\/JCO.2003.12.086","volume":"21","author":"DB Duggan","year":"2003","unstructured":"Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, et al. Randomized comparison of ABVD and MOPP\/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol. 2003;21(4):607\u201314. https:\/\/doi.org\/10.1200\/JCO.2003.12.086.","journal-title":"J Clin Oncol"},{"issue":"15","key":"8683_CR30","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1182\/blood-2017-10-772665","volume":"131","author":"PJ Brockelmann","year":"2018","unstructured":"Brockelmann PJ, Sasse S, Engert A. Balancing risk and benefit in early-stage classical Hodgkin lymphoma. Blood. 2018;131(15):1666\u201378. https:\/\/doi.org\/10.1182\/blood-2017-10-772665.","journal-title":"Blood"},{"issue":"1","key":"8683_CR31","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/bjh.15622","volume":"184","author":"J Longley","year":"2019","unstructured":"Longley J, Johnson PWM. Current treatment paradigms for advanced stage Hodgkin lymphoma. Br J Haematol. 2019;184(1):60\u201371. https:\/\/doi.org\/10.1111\/bjh.15622.","journal-title":"Br J Haematol"},{"issue":"15","key":"8683_CR32","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1182\/blood-2017-09-772640","volume":"131","author":"SH Lim","year":"2018","unstructured":"Lim SH, Johnson PWM. Optimizing therapy in advanced-stage Hodgkin lymphoma. Blood. 2018;131(15):1679\u201388. https:\/\/doi.org\/10.1182\/blood-2017-09-772640.","journal-title":"Blood"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08683-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08683-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08683-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T20:02:53Z","timestamp":1629921773000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08683-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,25]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8683"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08683-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,25]]},"assertion":[{"value":"16 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"955"}}